Assignee
VERNALIS R&D LTD
GB·26 granted patents·14 pending applications·94 citations·filing 2002–2020
Top patents by PatentIndex Score
40 records- 0196US8987279B2Triazolo [4, 5-D] pyramidine derivatives and their use as purine receptor antagonistsVERNALIS R&D LTD·Filed 2013·Granted Mar 24, 2015·40 cites·16 claims
- 0294US9376443B2Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonistsVERNALIS R&D LTD·Filed 2015·Granted Jun 28, 2016·11 cites·20 claims
- 0393US9765080B2Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonistsVERNALIS R&D LTD·Filed 2016·Granted Sep 19, 2017·9 cites·4 claims
- 0484US9475800B2Azetidine derivativesVERNALIS R&D LTD·Filed 2015·Granted Oct 25, 2016·4 cites·13 claims
- 0582US10875868B2Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonistsVERNALIS R&D LTD·Filed 2019·Granted Dec 29, 2020·0 cites·3 claims
- 0682US10413550B2Isoxazole compounds as inhibitors of heat shock proteinsVERNALIS R&D LTD·Filed 2017·Granted Sep 17, 2019·2 cites·28 claims
- 0780US9718793B2Isoxazole compounds as inhibitors of heat shock proteinsVERNALIS R&D LTD·Filed 2013·Granted Aug 1, 2017·3 cites·29 claims
- 0879US10383871B2Azetidine derivativesVERNALIS R&D LTD·Filed 2016·Granted Aug 20, 2019·2 cites·13 claims
- 0977US11466019B2Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonistsVERNALIS R&D LTD·Filed 2020·Granted Oct 11, 2022·0 cites·4 claims
- 1076US11234987B2Isoxazole compounds as inhibitors of heat shock proteinsVERNALIS R&D LTD·Filed 2019·Granted Feb 1, 2022·0 cites·29 claims
- 1176US10000481B21H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitorsVERNALIS R&D LTD·Filed 2013·Granted Jun 19, 2018·5 cites·22 claims
- 1276US9006269B2Azetidine derivativesVERNALIS R&D LTD·Filed 2013·Granted Apr 14, 2015·2 cites·10 claims
- 1376US8354415B2Thienopyrimidine compounds and compositionsVERNALIS R&D LTD·Filed 2008·Granted Jan 15, 2013·3 cites·26 claims
- 1476US7666876B2Buprenorphine formulations for intranasal deliveryVERNALIS R&D LTD·Filed 2002·Granted Feb 23, 2010·8 cites·26 claims
- 1575US10556911B2Thienopyrimidine compoundsVERNALIS R&D LTD·Filed 2018·Granted Feb 11, 2020·1 cites·36 claims
- 1675US9920066B2Thienopyrimidine compoundsVERNALIS R&D LTD·Filed 2017·Granted Mar 20, 2018·1 cites·8 claims
- 1774US7875600B2Pyrimidine compounds as purine receptor antagonistVERNALIS R&D LTD·Filed 2005·Granted Jan 25, 2011·2 cites·4 claims
- 1871US9610290B2Thienopyrimidine compoundsVERNALIS R&D LTD·Filed 2015·Granted Apr 4, 2017·1 cites·24 claims
- 1970US10538526B2Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonistsVERNALIS R&D LTD·Filed 2018·Granted Jan 21, 2020·0 cites·4 claims
- 2068US10106547B2Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonistsVERNALIS R&D LTD·Filed 2017·Granted Oct 23, 2018·0 cites·5 claims
- 2167US11028097B2Thienopyrimidine compoundsVERNALIS R&D LTD·Filed 2019·Granted Jun 8, 2021·0 cites·20 claims
- 2267US10918640B2Azetidine derivativesVERNALIS R&D LTD·Filed 2019·Granted Feb 16, 2021·0 cites·15 claims
- 2367US2010041624A1Buprenorphine formulations for intranasal deliveryVERNALIS R&D LTD·Filed 2009·Application pending·0 cites
- 2464US2020361905A1Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory ActivityVERNALIS R&D LTD·Filed 2020·Application pending·0 cites
- 2560US2021206762A11h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitorsVERNALIS R&D LTD·Filed 2020·Application pending·0 cites
- 2659US10696652B2Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activityVERNALIS R&D LTD·Filed 2018·Granted Jun 30, 2020·0 cites·16 claims
- 2759US9604975B2Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activityVERNALIS R&D LTD·Filed 2014·Granted Mar 28, 2017·0 cites·14 claims
- 2854US10889582B21H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitorsVERNALIS R&D LTD·Filed 2018·Granted Jan 12, 2021·0 cites·19 claims
- 2954US2017298043A1Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory ActivityVERNALIS R&D LTD·Filed 2017·Application pending·0 cites
- 3052US2011105551A1Analgesics for nasal administrationVERNALIS R&D LTD·Filed 2011·Application pending·0 cites
- 3148US7358265B2Oxa-and thiadiazoles and their use as metalloproteinase inhibitorsVERNALIS R&D LTD·Filed 2003·Granted Apr 15, 2008·0 cites·33 claims
- 3248US2010305143A1Pyrrolopyrimidine compoundsVERNALIS R&D LTD·Filed 2008·Application pending·0 cites
- 3347US2009181989A1Purine Compunds as HSP90 Protein Inhibitors for the Treatment of CancerVERNALIS R&D LTD·Filed 2009·Application pending·0 cites
- 3446US2009054421A1Pyrimidothiophene Compounds Having HSP90 Inhibitory ActivityVERNALIS R&D LTD·Filed 2006·Application pending·0 cites
- 3545US2010010037A11h-pyrrolo[2,3-b]pyridine derivatives useful as hsp90 inhibitorsVERNALIS R&D LTD·Filed 2007·Application pending·0 cites
- 3644US2009023697A1Analgesia methodVERNALIS R&D LTD·Filed 2007·Application pending·0 cites
- 3743US2010204224A1Azacyclic compounds as inhibitors of sensory neurone specific sodium channelsVERNALIS R&D LTD·Filed 2006·Application pending·0 cites
- 3843US2010105651A1Antagonists of sns sodium channelsVERNALIS R&D LTD·Filed 2006·Application pending·0 cites
- 3942US2009163490A1Pyrrolopyrimidine Derivatives Used As HSP90 InhibitorsVERNALIS R&D LTD·Filed 2007·Application pending·0 cites
- 4034US2009131470A1Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disordersVERNALIS R&D LTD·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when VERNALIS R&D LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →